Skip to main content
Median Technologies logo

Median Technologies — Investor Relations & Filings

Ticker · ALMDT ISIN · FR0011049824 LEI · 9695007YG6O07A8N6395 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 797 across all filing types
Latest filing 2025-04-24 Earnings Release
Country FR France
Listing PA ALMDT

About Median Technologies

https://mediantechnologies.com/

Median Technologies develops and provides innovative imaging solutions and services focused on oncology. The company utilizes proprietary artificial intelligence, computer vision, and signal processing technologies to transform medical images into actionable clinical insights. These insights aid healthcare professionals in the diagnosis, treatment, and monitoring of cancer. Median Technologies serves two primary markets: biopharmaceutical companies, by providing imaging services for oncology clinical trials, and healthcare providers, by offering software for clinical practice, including cancer screening. Its portfolio includes the eyonis® platform, designed for the early detection of cancer.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 100% confidence The document is explicitly titled "Communiqué de presse – Pour diffusion immédiate" (Press Release – For immediate release) and announces key financial indicators for the first quarter of 2025 (Q1 2025), including revenue figures and order book status. This format, focusing on key highlights immediately following the end of a reporting period, aligns perfectly with the definition of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on highlights and operational updates rather than detailed financial statements, and it is not an announcement of a report (RPA) because it contains the actual results. Filing Period: Q1 2025. Content: Key financial metrics and operational updates. Document Type: Earnings Release. Q1 2025
2025-04-24 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release dated April 7, 2025, titled "Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2025." It explicitly cites French regulatory articles (Code de Commerce and AMF General Regulations) and provides the exact breakdown of total shares and voting rights. This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory announcement. It does not fit the definitions for Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Dividend Notice (DIV). It is a specific regulatory disclosure concerning share capital, which aligns best with 'Share Issue/Capital Change' (SHA) or, given its nature as a mandatory regulatory disclosure not covered by other specific codes, potentially 'Regulatory Filings' (RNS). However, since it directly reports on the number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is a strong candidate. Looking at the definitions, SHA is for 'new share issues, stock splits, or other capital changes.' While this is a reporting of the *current* state of capital, it is closely related. The most precise fit among the options for a mandatory disclosure of the total number of shares and voting rights, often required periodically, is often categorized under general regulatory filings if a more specific code isn't available. Given the options, and recognizing this is a mandatory disclosure about the capital base, SHA is plausible, but DVA (Declaration of Voting Results & Voting Rights Announcements) is also a possibility, although DVA usually refers to the *results* of a vote, not the total rights count. Since the document explicitly details the 'total number of voting rights' and 'number of shares in the capital,' this is a direct report on the capital structure. SHA (Share Issue/Capital Change) is the closest fit for reporting on the number of shares outstanding, even if it's a periodic update rather than an issuance event. If SHA is interpreted strictly as issuance/splits, then RNS (Regulatory Filings) is the fallback. Given the content is a direct report on the capital base (shares and voting rights), I will classify it as SHA, as it pertains directly to the share capital structure.
2025-04-07 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release dated April 7, 2025, titled "Déclaration du nombre total de droits de vote et du nombre d'actions composant le capital au 31 mars 2025" (Declaration of the total number of voting rights and the number of shares comprising the capital as of March 31, 2025). It explicitly cites French regulatory articles (Code de commerce and AMF General Regulation) regarding the declaration of total voting rights. This content directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which covers official results from shareholder votes or related statutory declarations about voting rights structure.
2025-04-07 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is explicitly titled "Communiqué de presse – Pour diffusion immédiate" (Press Release – For immediate release) and is dated March 31, 2025. It announces the final results of the RELIVE study confirming the efficacy and safety of their medical device software, eyonis™ LCS, and provides timelines for regulatory submissions (FDA 510(k) in May 2025, CE marking in June 2025) and commercial launch plans. This content structure—a brief announcement highlighting key achievements, regulatory milestones, and future plans, often released outside of standard quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on operational/clinical milestones rather than just financial results (which would be ER), and it is a formal announcement, it fits best as an Earnings Release (ER) if we consider clinical/regulatory progress as key performance indicators, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the focus on study results and regulatory timelines, it is a primary announcement of operational progress, aligning closely with the intent of an Earnings Release (ER) which often includes operational highlights alongside financial data, or a general press release. Since 'ER' covers initial announcements of periodical financial results, and this is a major operational/clinical update, it is the most appropriate fit among the specific options, as it is not a full report (10-K, IR) or a simple notice of publication (RPA). Q1 2025
2025-03-31 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is explicitly titled as a "Press release – For immediate release" dated March 31, 2025. It announces the final results of a pivotal study (RELIVE) for a product (eyonis™ LCS) and provides updates on regulatory filing timelines (U.S. FDA 510(k) in May 2025, CE marking in June 2025) and commercial launch plans (Q4 2025). This content structure—announcing key operational/clinical milestones and future regulatory steps via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive financial report (like 10-K or IR) but rather a specific operational update intended for immediate public dissemination, 'ER' (Earnings Release) is the most appropriate fit, as these releases often contain key operational highlights alongside any associated financial context, or serve as the primary vehicle for material non-earnings news when a formal earnings report isn't due. Given the focus on study results and regulatory milestones, it functions as a material announcement. If the document were purely a regulatory filing notification without the press release format, RNS might apply, but the format strongly suggests ER or RNS. ER is chosen because it details significant operational achievements that drive future performance, which is a core component of earnings-related announcements. Q1 2025
2025-03-31 English
Etat membre d'origine / Choix de l’autorité compétente pour le contrôle de l’information réglementée
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 14, 2025, announcing that Median Technologies meets the eligibility conditions for the PEA-PME scheme, which relates to capital structure and tax advantages for investors. This type of announcement, concerning eligibility for a specific financial/tax scheme related to capital, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it directly addresses the company's eligibility for a specific equity savings plan scheme, CAP is the most appropriate classification.
2025-03-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.